Skip to main content
. 2017 Mar 23;2(6):e83527. doi: 10.1172/jci.insight.83527

Figure 1. CHIKV vaccines and immunizations.

Figure 1

(A) Vaccine constructs are based on the LR-CHIKV strain LR-2006OPY1. Top, Δ5nsP3, (Δ5), an infectious attenuated virus carrying a 60 amino acid–long deletion in the nsP3 replicase protein (9). Middle, the DREP-E (D) replicon DNA vaccine (9). Bottom, the recombinant modified vaccinia virus Ankara MVA-CE (M) vaccine (8) has a cDNA copy of the CHIKV structural gene cassette (C-E3-E2-6K-E1) inserted into the MVA genome and is expressed under the control of the MVA sE/L promoter. (B) Immunization schedule of cynomolgus macaques. Group Δ5nsP3-A received one s.c. injection of 1 × 105 PFU of Δ5 virus on day 42 (red arrow). Group Δ5nsP3-B received one s.c. injection of 1 × 105 PFU of Δ5 virus on day 0 (red arrow). Group DREP-E received 200 μg of D by intradermal (i.d.) injection followed by electroporation (EP) on days 0 and 42 (green arrows). Group DREP-E+MVA-CE was primed on day 0 with 200 μg of D followed by an i.m. injection of 1 × 108 PFU of M on day 42 (blue arrows). Group 4 (controls) received 0.9% NaCl injections i.d. followed by EP on day 0 and s.c, i.m., and i.d. injections followed by EP on day 42 (orange arrows). All animals were challenged with 100 animal infectious doses 50% (AID50) WT LR-CHIKV on day 123 for groups 1A, 2, 3, and 4 and on day 294 for group 1B (black arrows). The study ended on day 298 for all groups except group 1B, which ended on day 359.